Aquestive Therapeutics (NASDAQ:AQST) Rating Reiterated by JMP Securities

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “market outperform” rating reaffirmed by equities research analysts at JMP Securities in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $9.00 price target on the stock. JMP Securities’ price target indicates a potential upside of 89.08% from the company’s previous close.

Several other equities research analysts have also recently commented on the stock. Leerink Partners reiterated an “outperform” rating and issued a $12.00 price target (up from $10.00) on shares of Aquestive Therapeutics in a research report on Monday. HC Wainwright boosted their target price on shares of Aquestive Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Monday. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $8.67.

Aquestive Therapeutics Trading Down 4.4 %

AQST stock opened at $4.76 on Monday. The firm’s 50-day moving average is $4.26 and its two-hundred day moving average is $3.68. The company has a market capitalization of $433.35 million, a price-to-earnings ratio of -11.33 and a beta of 2.84. Aquestive Therapeutics has a 52 week low of $1.25 and a 52 week high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.08. The firm had revenue of $20.10 million during the quarter, compared to analyst estimates of $12.62 million. During the same quarter last year, the company earned ($0.10) earnings per share. On average, equities research analysts predict that Aquestive Therapeutics will post -0.47 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in AQST. Victory Capital Management Inc. acquired a new position in Aquestive Therapeutics during the second quarter valued at $27,000. SG Americas Securities LLC purchased a new stake in shares of Aquestive Therapeutics in the first quarter worth approximately $54,000. Lazard Asset Management LLC boosted its holdings in shares of Aquestive Therapeutics by 115.5% during the first quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after purchasing an additional 15,601 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in shares of Aquestive Therapeutics during the second quarter worth approximately $76,000. Finally, Financial Advocates Investment Management grew its position in Aquestive Therapeutics by 70.0% during the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock valued at $88,000 after purchasing an additional 14,000 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.